Blog & Resources Camargo Blog December 7th, 2007

505(b)(2)—Part 2: The Assessment: Clinical Pharmacology

Clinical Pharmacology

An overview of the proposed product’s absorption, distribution, metabolism, and excretion (ADME) is detailed in this section obtained from various resources. An important source of information for this and other sections is the FDA reviewer summaries (Summary Basis of Approval – SBA) for the reference listed drug (RLD) as well as other drugs in the therapeutic class. An example SBA is found here. Of course, should we be proposing to change the route of administration, it will be important to determine how this route may change the clinical pharmacology. This information will drive the clinical studies that will be needed.

[1] PDR® Electronic LibraryTM [Internet database]. Greenwood Village, Colo: Thomson Micromedex. Updated periodically.[2] Facts and Comparisons 4.0, Wolters Kluwer Health,

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights